Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Esperion Therapeutics, Inc.
- Study ID
- NCT02988115
- Phase
- PHASE3
- Status
- Completed
Conditions
- Atherosclerotic Cardiovascular Disease
- Hypercholesterolemia
- Statin Adverse Reaction
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bempedoic acid — DRUGbempedoic acid 180 mg tablet
- placebo — OTHERMatching placebo tablet
Study Details
The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.
Key Dates
- Start date
- Nov 16, 2016
- Status verified
- Mar 2020
- Primary completion
- Mar 16, 2018
- Completion
- Mar 16, 2018
Study Design
- Enrollment
- 345 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: bempedoic acidbempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
- Placebo Comparator: placeboMatching placebo tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
Primary Outcome Measure
Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 [ Time Frame: Baseline; Week 12 ]
Locations (52)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Gilbert | Arizona | - | - |
| - | Anaheim | California | - | - |
| - | Long Beach | California | - | - |
| - | Sacramento | California | - | - |
| - | Santa Ana | California | - | - |
| - | Torrance | California | - | - |
| - | Ventura | California | - | - |
| - | Hamden | Connecticut | - | - |
| - | Daytona Beach | Florida | - | - |
| - | Fort Lauderdale | Florida | - | - |
| Site 1 | Miami | Florida | - | - |
| Site 2 | Miami | Florida | - | - |
| - | Orlando | Florida | - | - |
| - | West Palm Beach | Florida | - | - |
| - | Atlanta | Georgia | - | - |
| - | Savannah | Georgia | - | - |
| - | Meridian | Idaho | - | - |
| - | Evanston | Illinois | - | - |
| - | Evansville | Indiana | - | - |
| - | Iowa City | Iowa | - | - |
| - | Waterloo | Iowa | - | - |
| - | Monroe | Louisiana | - | - |
| - | Slidell | Louisiana | - | - |
| - | Tupelo | Mississippi | - | - |
| - | Lincoln | Nebraska | - | - |
| - | Somerset | New Jersey | - | - |
| - | Binghamton | New York | - | - |
| - | Endwell | New York | - | - |
| - | New Windsor | New York | - | - |
| - | Greensboro | North Carolina | - | - |
| - | Morganton | North Carolina | - | - |
| - | Mount Airy | North Carolina | - | - |
| - | Columbus | Ohio | - | - |
| - | Marion | Ohio | - | - |
| - | Maumee | Ohio | - | - |
| - | Oklahoma City | Oklahoma | - | - |
| - | Beaver | Pennsylvania | - | - |
| - | Langhorne | Pennsylvania | - | - |
| - | Cumberland | Rhode Island | - | - |
| - | Anderson | South Carolina | - | - |
| - | Summerville | South Carolina | - | - |
| - | Jackson | Tennessee | - | - |
| - | Knoxville | Tennessee | - | - |
| - | Memphis | Tennessee | - | - |
| - | Amarillo | Texas | - | - |
| Site 1 | Dallas | Texas | - | - |
| Site 2 | Dallas | Texas | - | - |
| - | Houston | Texas | - | - |
| - | San Antonio | Texas | - | - |
| - | Clinton | Utah | - | - |
| - | Hampton | Virginia | - | - |
| - | Kenosha | Wisconsin | - | - |
Find similar trials in Gilbert, AZ
Related Studies
- Alirocumab in Patients on a Stable Dialysis RegimenPHASE3 · Recruiting · Baylor Research Institute · Dallas, Texas
- Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders TrialPHASE2 · Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
- The Prevent Coronary Artery Disease TrialPHASE3 · Recruiting · Icahn School of Medicine at Mount Sinai · New York, New York
- Pharmacogenomic Informed Statin PrescribingRecruiting · VA Office of Research and Development · Indianapolis, Indiana